Gus Scacco Shares How AI Is Powering the Next Wave of Drug Discovery on Fox Business
Advisors Capital Management Portfolio Manager, Gus Scacco, joined Fox Business to discuss how artificial intelligence is accelerating breakthroughs in biotechnology, reshaping consumer platforms, and supporting continued market strength as the Dow hits historic highs.
In his Countdown Closer segment with host Liz Claman, Gus explains why Thermo Fisher stands out as a long-term opportunity, and why today’s AI boom is far larger than a tech story alone.
Gus Scacco breaks down biotech, AI, and what a 48,000 Dow means for investors.
Key Highlights
AI Is Accelerating Drug Discovery
Thermo Fisher’s newly FDA-approved Extend System enables faster, more precise identification of conditions like multiple myeloma. Advances in AI-driven protein mapping are laying the groundwork for the next wave of drug development, supporting stronger sales and long-term growth.
Strong Momentum for Thermo Fisher
Thermo Fisher shares are up more than 21% quarter-to-date, supported by rising expectations and continued execution. Improved outlooks across life sciences and applied research point to potential further gains.
AI’s Impact Reaches Beyond Tech
AI is reshaping industries far beyond semiconductors. In consumer platforms such as eBay, AI is improving clickthrough rates, reducing language barriers, and enhancing sales efficiency. Across the economy, AI-driven productivity gains continue to lift corporate performance.
Market Strength Fueled by Earnings
The Dow’s first-ever close above 48,000 reflects a market driven by strong fundamentals. Earnings grew 13% last quarter—well above expectations—and margin expansion is being supported by productivity improvements. AI-related data-center investment is contributing an estimated 1% to U.S. GDP, reinforcing the broader economic backdrop.